If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-11. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
=== Transitioning to commercial release (2013–2014) === A new version of the Source engine had been introduced by 2013 that, in addition to new engine features, included support for OS X and Linux platforms. However, developers had to pay to gain access to the full feature set of this engine. According to Adam Engels, the project lead at the completion of Black Mesa, Valve approached their team around this time and suggested making Black Mesa a commercial release and, thus, getting a license to the Source engine. The team considered this option, and, since access to the full Source engine would help make Black Mesa the best game they could, opted to go the commercial route to be able to pay for that license, not having originally intended to profit from the game. By November 2013, the team had affirmed that they had gotten Valve's permission to sell the game. Some of the team were later invited to Valve's offices in Bellevue, Washington in 2015. At this point in 2013, the team cautioned that a final version was still some distance away, as they were still dealing with the updated Source engine, and they had not yet done much with Xen. Crowbar Collective continued to offer the free version of Black Mesa, based on the earlier Source engine, on their website. With the new Source engine, the team started to look more closely at how Valve had used Source in Half-Life 2, compared to what they had done in the original Half-Life, and developed changes for Black Mesa that reflected what they believed were Valve's design principles in Half-Life 2.
Substituted amphetamines are a class of compounds based upon the amphetamine structure; it includes all derivative compounds which are formed by replacing, or substituting, one or more hydrogen atoms in the amphetamine core structure with substituents. Examples of substituted amphetamines are amphetamine (itself), methamphetamine, ephedrine, cathinone, phentermine, mephentermine, bupropion, methoxyphenamine, selegiline, amfepramone, pyrovalerone, MDMA (ecstasy), and DOM (STP). Many drugs in this class work primarily by activating trace amine-associated receptor 1 (TAAR1); in turn, this causes reuptake inhibition and effluxion, or release, of dopamine, norepinephrine, and serotonin. An additional mechanism of some substituted amphetamines is the release of vesicular stores of monoamine neurotransmitters through VMAT2, thereby increasing the concentration of these neurotransmitters in the cytosol, or intracellular fluid, of the presynaptic neuron. Amphetamine-type stimulants are often used for their therapeutic effects. Physicians sometimes prescribe amphetamine to treat major depressive disorder, where subjects do not respond well to traditional selective serotonin reuptake inhibitor (SSRI) medications, but evidence supporting this use is mixed. Two large phase III studies of lisdexamfetamine (a prodrug to amphetamine) as an adjunct to an SSRI or serotonin–norepinephrine reuptake inhibitor (SNRI) in the treatment of major depressive disorder showed no further benefit relative to placebo in effectiveness.
The matrix built from blocks with less than r% of similarity E.g., BLOSUM62 is the matrix built using sequences with less than 62% similarity (sequences with ≥ 62% identity were clustered together). Note: BLOSUM 62 is the default matrix for protein BLAST. Experimentation has shown that the BLOSUM-62 matrix is among the best for detecting most weak protein similarities. Several sets of BLOSUM matrices exist using different alignment databases, named with numbers. BLOSUM matrices with high numbers are designed for comparing closely related sequences, while those with low numbers are designed for comparing distant related sequences. For example, BLOSUM80 is used for closely related alignments, and BLOSUM45 is used for more distantly related alignments. The matrices were created by merging (clustering) all sequences that were more similar than a given percentage into one single sequence and then comparing those sequences (that were all more divergent than the given percentage value) only; thus reducing the contribution of closely related sequences. The percentage used was appended to the name, giving BLOSUM80 for example where sequences that were more than 80% identical were clustered.
== Synonyms == In the 19th and the early 20th centuries, several synonyms were in use for erythritol: erythrol, erythrite, erythroglucin, eryglucin, erythromannite and phycite. Zerose is a tradename for erythritol.
== Receptors == Relaxin interacts with the relaxin receptor LGR7 (RXFP1) and LGR8 (RXFP2), which belong to the G protein-coupled receptor superfamily. They contain a heptahelical transmembrane domain and a large glycosylated ectodomain, distantly related to the receptors for the glycoproteohormones, such as the LH-receptor or FSH-receptor. Relaxin receptors have been found in the heart, smooth muscle, the connective tissue, and central and autonomous nervous system.
Sources: en.wikipedia.org
Map of Mexican drug war violence Borderland Beat Blog dedicated to reporting on Mexican drug cartels on the border between the US and Mexico Bowers, Charles (2009). "The Mexican Kidnapping Industry". Archived from the original on February 23, 2015. Retrieved April 9, 2009. An academic paper examining both the emergence of kidnapping as a drug war spillover, and statewide variance in Mexico's kidnapping statutes. The Mexican Zetas and Other Private Armies – written by the Strategic Studies Institute. Mexico page on InSight Crime. Ongoing reporting on Mexico's drug war and the involved cartels. "Full Coverage Mexico Under Siege". Los Angeles Times. Archived from the original on April 6, 2014. Retrieved September 12, 2016. The Atlantic: Mexico's Drug War George Grayson, "Mexico's Elite Must Commit to Fighting Drug Cartels", Foreign Policy Association Headline Series. Juarez, City of Death, City of Hope Cocaine Incorporated June 15, 2012 How American guns turned Mexico into a war zone (by Stuart Miller, LA Times, February 24, 2021)
Stretching of the atrial wall, via Atrial volume receptors Increased Sympathetic stimulation of β-adrenoceptors Increased sodium concentration (hypernatremia), though sodium concentration is not the direct stimulus for increased ANP secretion Endothelin, a potent vasoconstrictor Recently, it was discovered that ANP also can be O-glycosylated.
In 2010, Emma Fogarty, a campaigner for DEBRA Ireland (the EB charity), was awarded a People of the Year Award. Actor Colin Farrell has campaigned with Fogarty on behalf of affected people. In 2014, Pearl Jam lead vocalist Eddie Vedder together with his wife Jill McCormick co-founded the EB Research Partnership, a non-profit organization dedicated to finding a cure for EB. McCormick is childhood friends with Ryan Fullmer, whose son, Michael, was born with EB. Vedder, McCormick, Ryan Fullmer, and his wife Heather founded Heal EB. In 2014, they merged Heal EB with the Jackson Gabriel Research Foundation to create the EB Research Partnership. The EBRP hosts several annual fundraising events. To date, they have raised $12 million to fund research to find a cure. On 1 March 2019, heavyweight boxer Luis Ortiz was named an honorary ambassador for the EB community by the EB Research Partnership. Ortiz's daughter, Lismercedes, was born with EB.
== Medical uses == In the US, gabapentin is indicated for the treatment of postherpetic neuralgia and as an adjunctive therapy in the treatment of partial-onset seizures without secondary generalization in people with epilepsy. Gabapentin is recommended for use in focal seizures and neuropathic pain. Gabapentin is prescribed off-label in the US and the UK, for example, for the treatment of non-neuropathic pain, anxiety disorders, sleep problems and bipolar disorder. In recent years, gabapentin has seen increased use, particularly in the elderly. There is concern regarding gabapentin's off-label use due to the lack of strong scientific evidence for its efficacy in multiple conditions, its proven side effects and its potential for misuse and physical/psychological dependency. Some harms, including nervous system harms, have been underreported in published trials of gabapentin, potentially resulting in the underestimation of harms in guidelines for the use of gabapentin.
At the beginning of March 2016, Hangman's Chair performed at Le Mondial du Tatouage, a major annual international tattoo convention held at the Grande halle de la Villette in Paris. During a tour in Japan with Arkangel, Chanut met the members of Greenmachine. Hangman's Chair subsequently recorded a split album with Greenmachine, released in France through Music Fear Satan and in Japan through Daymare Recordings in February and March 2017, respectively. Jacob Bannon expressed appreciation for the split. A music video for "Can't Talk" was released; it was made by Hanvic using excerpts from one of Brigitte [Lahaie]'s old pornographic films.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.